Azor

Azor is a brand name of amlodipine/olmesartan, approved by the FDA in the following formulation(s):

AZOR (amlodipine besylate; olmesartan medoxomil - tablet; oral)

• 
  Manufacturer: DAIICHI SANKYO
  
  Approval date: September 26, 2007
  
  Strength(s): EQ 10MG BASE;20MG, EQ 10MG BASE;40MG ^[RLD], EQ 5MG BASE;20MG, EQ 5MG BASE;40MG
  

Has a generic version of Azor been approved?

No. There is currently no therapeutically equivalent version of Azor available.

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Azor. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

• 
  Angiotensin II antagosist 1-biphenylmethylimidazole compounds and their therapeutic use
  Patent 5,616,599
  Issued: April 1, 1997
  Inventor(s): Yanagisawa; Hiroaki & Fujimoto; Koichi & Amemiya; Yoshiya & Shimoji; Yasuo & Kanazaki; Takuro & Koike; Hiroyuki & Sada; Toshio
  Assignee(s): Sankyo Company, Limited
  Compounds of the following formula (I) or the formula (I).sub.p : ##STR1## wherein R.sup.1 is alkyl or alkenyl; R.sup.2 and R.sup.3 are hydrogen, alkyl, alkenyl, cycloalkyl, aralkyl, aryl, or aryl fused to cycloalkyl; R.sup.4 is hydrogen, alkyl, alkanoyl, alkenoyl, arylcarbonyl, alkoxycarbonyl, tetrahydropyranyl, tetrahydrothiopyranyl, tetrahydrothienyl, tetrahydrofuryl, a group of formula --SiR.sup.a R.sup.b R.sup.c, in which R.sup.a, R.sup.b and R.sup.c are alkyl or aryl, alkoxymethyl, (alkoxyalkoxy)methyl, haloalkoxymethyl, aralkyl, aryl or alkanoyloxymethoxycarbonyl; R.sup.5 is carboxy or --CONR.sup.8 R.sup.9, wherein R.sup.8 and R.sup.9 hydrogens or alkyl, or R.sup.8 and R.sup.9 together form alkylene; R.sup.6 is hydrogen, alkyl, alkoxy or halogen; R.sup.7 is carboxy or tetrazol-5-yl; R.sub.p.sup.1 is hydrogen, alkyl, cycloalkyl or alkanoyl; R.sub.p.sup.2 is a single bond, alkylene or alkylidene; R.sub.p.sup.3 and R.sub.p.sup.4 are each hydrogen or alkyl; R.sub.p.sup.6 is carboxy or tetrazol-5-yl; and X.sub.p is oxygen or sulfur; and pharmaceutically acceptable salts and esters thereof. The compounds are AII receptor antagonists and thus have hypotensive activity and can be used for the treatment and prophylaxis of hypertension. The compounds may be prepared by reacting a biphenylmethyl compound with an imidazole compound.
  
  Patent expiration dates:
  
  
  • April 25, 2016
    
    ✓ 
    Patent use: TREATMENT OF HYPERTENSION
    ✓ 
    Drug substance
    ✓ 
    Drug product
  
  
  
  • October 25, 2016
    
    ✓ 
    Pediatric exclusivity
  
  

Related Exclusivities

Exclusivity is exclusive marketing rights granted by the FDA upon approval of a drug and can run concurrently with a patent or not. Exclusivity is a statutory provision and is granted to an NDA applicant if statutory requirements are met.

• Exclusivity expiration dates:
  • September 26, 2010 - NEW COMBINATION
  
  

See also...

• Azor Consumer Information (Drugs.com)
• Azor Consumer Information (Wolters Kluwer)
• Azor Consumer Information (Cerner Multum)
• Azor Advanced Consumer Information (Micromedex)
• Amlodipine/Olmesartan Consumer Information (Wolters Kluwer)
• Amlodipine and olmesartan Consumer Information (Cerner Multum)
• Amlodipine and olmesartan Advanced Consumer Information (Micromedex)